People with depression often experience disabilities that limit their social and physical capacity, daily function, and quality of life. Depressive symptoms and their implications on daily activities are often measured retrospectively with subjective measurement tools. Recently, more objective and accurate electronic data collection methods have been used to describe the daily life of people with depressive disorders, but the results have not yet been systematically reviewed. We aim to provide a knowledge basis for the use of tracking technologies in examining life-space mobility among adults with depression and/or anxiety disorder.
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Other than as permitted in any relevant BMJ Author' Depression is ranked as the single largest contributor to global disability. It has been estimated that about 6% of the world's population suffer from depression. 1 In 2015, depression contributed 7.5% of all years lived with disability. 2 It is also a major contributor to suicide deaths, accounting for anywhere from half to two-thirds of suicide cases, which makes depression among the top 20 leading causes of death. 3 Depression results in high treatment costs for health care services and limits productivity in communities due to its associated long-term outcomes and high disability, compared to other chronic diseases. 3 4 In 2005, it was estimated that the direct and indirect costs of depression in Europe was 120 billion euros. 5 People with depression may experience various mental health effects, including persistently feeling low, a loss of interest and enjoyment, anxiety as comorbidity 2 and a range of emotional, cognitive, physical and behavioural symptoms, 6 which may cause those who suffer from depression to be reluctant to engage themselves in daily social activities and work. 7 It has already been shown in a European cohort study that adults with depression and/or anxiety disorder have a lower level of physical function compared to those without depression, where physical function referred to limitations in performing normal activities of daily living and mobility, such as personal hygiene and eating, or preparing meals and doing housework. 7 In institutional settings, among other factors, apathy and depressive symptoms in elderly people have been found to have the greatest potential for limiting one's life space. 8 The association between depressive symptoms and individual life space has been reported in previous studies. 9 10 Life space refers to the area of movement extending from within the home to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 the geographic area a person moves in daily, while life-space mobility is a measurement of the space through which a person moves over a specific period of time. 9 Life-space mobility is a way to view an individual's functioning and participation in real-world situations, as it measures the ability to walk, use public transportation or drive a car. 11 12 It is assumed that a larger life-space mobility provides more opportunities for an individual to engage with society, 13 while a restricted life-space mobility may reflect limited access to societal amenities. 14 15 It has been shown by Snih et al. that a high number of depressive symptoms is one of the contributing factors that is significantly associated with a lower level of life-space mobility. 10 Other studies have shown that a constricted life space may be related to negative health outcomes such as disability and cognition. 11 16-18 Boyle et al. 19 further indicate, in their prospective observational cohort study, that having a constricted life space is associated with a greater risk of mortality, while Cacioppo further proposes that having a larger life-space may contribute to the effective functioning of physiological systems, and therefore lead to better physical health outcomes. 20 Self-reported measurements have often been used to assess life-space mobility, yet although they can be helpful, they may tend to overestimate true mobility and underestimate sedentary time. 21 22 Therefore, more accurate and objective methods to detect human mobility are needed. 23 Significant correlations between objective features and depressive mood symptoms have provided new opportunities to use mobile applications and wearable devices for monitoring depression and other affective disorders. 24 It has been assumed that technological devices can easily and objectively provide a way to monitor activity of people with these illnesses and could serve as a digital marker of mood symptoms. 25 26 We found two reviews related to the assessment of individual mobility using technological devices in patients with mental disorders. Burton 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 practice to gain more understanding of these people's daily life. If a deeper knowledge would be available about different technological devices and how these could be used to collect information of digital markers of life-space mobility in real-life community settings, 27 we would have better opportunities to tailor individuals' treatment plans based on their daily functioning and habits.
Based on this knowledge, ideas for future development needs of technological devices could also be offered. However, in order to do this, we first need more knowledge about the tracking methods available and how these methods are used on a daily basis, keeping in mind their possible benefits and concerns.
AIM AND RSEARCH QUESTIONS
The overall aim of this systematic review is to describe the tracking technologies used in understanding life-space mobility among adults with depression and/or anxiety disorder. The review questions are as follow: (1) What types of technology has been used in tracking life-space mobility among people with depression and/or anxiety disorder? (2) How has the technology been used in tracking life-space mobility among people with depression and/or anxiety disorder? (3) What are the outcomes and measurements used in tracking life-space mobility among people with depression and/or anxiety disorder? (4) What is the life-space mobility pattern based on tracking data among people with depression and/or anxiety disorder?
This systematic review protocol is designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement Protocols (PRISMA-P), 29 and this guideline is usable because PRISMA-P focuses on ways in which authors can ensure the transparent and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8 complete reporting of systematic reviews and meta-analyses. 30 The protocol has been registered in PROSPERO (number CRD42019127102).
METHODS AND ANALYSIS Design
A systematic review with narrative synthesis will be used to search, appraise and synthesise empirical evidence. This approach is useful for our purpose because narrative synthesis focuses on a wide range of questions, not only those relating to the effectiveness of a particular intervention. 31
Eligibility criteria
Studies using any type of research design will be included as long as the study includes a description of the tracking technology used. Studies should include adult participants of both genders. Participants with symptoms of depression and/or anxiety or a specific diagnosis will be included. Regarding life-space studies, all studies in which any type of tracking technology is used will be included. Tracking technology can include mHealth methods, such as mobile health or wireless health, which refers to portable internal and wearable sensors to monitor health. 32 Other methods can include, for example, accelerometers, gyroscopes, vector magnetometers, goniometers, piezoelectric, and textile pressure sensors, electromyography, tilt/bend sensors and the global positioning system (GPS), which are able to measure the type, quantity, and quality of daily activity, movement and balance. 32 Studies will be limited to peer-reviewed, published fulltext articles. There will be no restriction regarding the language. We will exclude studies where subjects are diagnosed with bipolar disorder, schizophrenia, learning disabilities or other serious cognitive disorders. Studies involving only children or adolescents will also be excluded. Studies using self-recorded methods, questionnaires or nondigitally based tracking technology will not be considered. In addition, theoretical papers, statistical reviews, books or book chapters, letters, dissertations, editorials and study protocols will be excluded.
Information sources
A comprehensive literature search with no specific year limits will be conducted. The following electronic databases will be searched: MEDLINE (via EbscoHost), CINAHL Complete, PsycINFO, Embase, the Cochrane Library (academic database for medicine and health science and nursing), Scopus, Web of Science (academic database across all scientific and technical disciplines, ranging from medicine and social sciences to arts and humanities), 33 Health technology assessment database (database for health technology) and IEEE Xplore (academic database for technology and engineering). These databases will be used because they allow us to search for literature widely in various disciplines related to our review topic. Moreover, a reference list of the selected papers will be screened to yield additional studies.
Search strategy
The search strategy will be elaborated upon and implemented prior to the study selection. We will use the PRISMA-P checklist for guidance. 29 Firstly, the existence of a controlled vocabulary thesaurus (such as MeSH terms, CINAHL headings, PsycINFO thesaurus) and their keywords will be verified in each database. The search terms will be combined using the Boolean operators "AND" and "OR". Second, the following string of search terms will be used to ensure a broad coverage of published studies in this review: ("depression" OR "affective disorder*" OR "anxiety" OR "anxiety disorder*" OR "mental health" OR "mood disorder*" OR "unipolar" OR "mental disorder*") AND ("tracking" OR "tracking device*" OR "tracking technology*" OR "wearable device*" OR "wearable sensor*" OR "wearable technology*" OR "technology*") AND ("mobility" OR "life space"). Advice on searching will be sought from a faculty librarian regarding the keywords. An example of databases and search terms used, and references found is presented in Table 1 .
ANALYSIS

Data management
EndNote will be used to efficiently manage the retrieved records to help in documenting the process, streamlining document management and making the production of reference lists for reports and journal papers. EndNote will also be used to deal with duplications of selected papers and ensure that they are not treated as separate studies in the review. 34
Selection process
There will be four steps in the study selection process ( Figure 1 ). 30 First, titles and abstracts will be assessed by relevance to the inclusion criteria by two authors (CMH, MV) independently.
Second, the abstract of the papers will be screened for relevance and eligibility again by the same two authors (CMH, MV). Third, the full texts of the selected articles will be screened by the two authors (CMH, MV) for inclusion and exclusion criteria. In cases of any discrepancy on decisions made by the two authors, the paper will be discussed with another author (LSF). Papers that do not meet the inclusion criteria will be rejected, and the reason (irrelevance or failure to meet the inclusion criteria) will be recorded to increase the transparency in the selection process. Fourth, the full texts of the studies that meet the inclusion criteria will be obtained for further detailed assessment. The reference lists of selected papers will also be screened and checked to find additional papers that meet the inclusion criteria.
Data collection process
Specific tables will be created to collect information from selected papers to answer the review questions. Data will be extracted by one author (CMH) and reviewed for completeness and accuracy by another author (MV).
Characteristics of the studies
The following information of data items will be collected to describe the characteristics of each study: name(s) of the author(s), year of publication, country where the study was conducted, purpose of the study, setting, type of study, study design, and population/sample size (response rate).
Type of the tracking technology used
Details of tracking technologies used will be extracted: tracking technology used, characteristics of the tracking technology, administrator, length of tracking period, and possible challenges in using the tracking technology. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Extraction of the following information related to daily activity and community participation among the participants will be collected: specific outcomes, instruments used to measure the outcomes, the number of items and scoring for the instruments (total scale/subscales), and validity and reliability.
Type of outcome measure and instruments used in the tracking studies
Daily activity and community participation pattern among the participants
The following information of data items will be extracted to describe the daily activity and community participation patterns among the participants: the number of activities per day, time of day, type of activity, destination of the activity, and duration of activity.
Data extraction
Data of the selected papers will be extracted by one author (CMH) and inputted into predesigned tables to describe the characteristics of the included studies and to answer each review question;
the process will be validated by MV. The division into tables will be reviewed by all authors.
Data synthesis
Initial descriptive synthesis will be conducted by tabulating details about study type, interventions, numbers of participants, and an overview of participant characteristics, to form a clear descriptive summary of the included studies. 34 The descriptive process will be conducted explicitly and rigorously, and decisions about how to group and tabulate data will be made based on the protocol and review questions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The quality of each study will be appraised using The Crowe Critical Appraisal Tool (CCAT).
Risk of bias in individual studies
The Crowe Critical Appraisal Tool has been designed based on a review of the design of 44 critical appraisal tools across all research designs. [35] [36] [37] [38] The tool consists of eight categories (preliminaries, introduction, design, sampling, data collection, ethical matters, results and discussion) divided into 22 items, which are further divided into 98 item descriptors. 35 The combination of categories, items and item descriptors allows for a wide range of qualitative and quantitative health research to be appraised using one tool. [35] [36] [37] The scoring of the tool offers a combination of subjective and objective assessment. Each category is scored from 0 (the lowest score) to 5 (the highest score).
The total score given to a paper can be expressed as a percentage by dividing the total by 40.
In addition, the Cochrane Collaboration's tool for assessing risk of bias in randomised trials will be used to assess the quality of selected randomised trial articles included in the review. 38 Each area to be assessed will be rated as "low risk", "high risk" or "unclear risk" of bias, and finally, overall quality of the article using RCT design will be rated as "good", "fair" or "poor".
Patient and public involvement
Patients will not be directly involved in the design of this study. As this is a protocol for a systematic review and no participant recruitment will take place, their involvement in the recruitment and the dissemination of findings to participants will not be applicable. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Any amendments to this protocol will be documented with reference to saved searches and analysis methods, which will be recorded in bibliographic databases (Ovid), EndNote and Excel templates for data collection and synthesis.
Amendments
Dissemination
The results of the review will be disseminated in an open access journal to ensure access for undergraduate and graduate students, researchers, academics and research groups, and will also be disseminated through various media outlets, such as conferences, seminars, congresses or symposia.
DISSCUSSION
There are a number of strengths of the proposed review. First, this systematic review protocol increases the transparency of the review process, improves the systematic approach, reduces biases and opens the planned steps to the reviewers, thereby decreasing possible manipulation of the data.
Second, this review will provide evidence of the use of tracking technologies in studying the lifespace mobility of adults with depression and/or anxiety disorder, which may provide new opportunities for further studies. Third, this review will be the first to combine the knowledge about existing tracking technology to be used to explore the life-space mobility among people with depression in real-time and real-world urban settings. However, the high heterogeneity of the tracking technology use in order to have clear conclusions for the clinical practice may be the main limitation of the study. In conclusion, this systematic review will provide the best example of the use of tracking technologies in studying life-space mobility of adults with depression and/or anxiety disorder. The results from the review will inform and guide a future study on describing life-space mobility among people with depression in real-time and real-world urban settings in Hong Kong. Further, the results will provide insights for tailor-made rehabilitation services and policies, based on individual's concerns and needs.
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Methods and analysis:
A systematic review with a narrative approach for different types of study design will be conducted. The following databases will be used to gather information from 1994 to the present: MEDLINE, CINAHL, PsycINFO, Embase, the Cochrane Library, Scopus, Web of Science, Health technology assessment database and IEEE Xplore databases. The study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement Protocols (PRISMA-P). The methodological appraisal of the studies will be assessed by The
Crowe Critical Appraisal Tool as well as Cochrane Risk-of-Bias Tool for RCTs. A narrative synthesis will be conducted for all included studies.
Ethics and dissemination:
Because there will be no human involvement in the actual systematic review, no ethical approval will be required. The results will be disseminated in a peer-review journal and a conference presentation.
Trial registration number: PROSPERO number CRD42019127102.
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Strengths and limitations of this study  To the best of our knowledge, this systematic review will be the first to combine the knowledge about existing tracking technology used to explore life-space mobility among people with depression and/or anxiety disorder in real-time and in real-world urban settings.  Methods used in this review will be reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Statement Protocols (PRISMA-P).  This review increases the transparency of the review process, improves the systematic approach, reduces biases and informs the reviewers of the planned steps, thereby decreasing possible manipulation of the data. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
INTRODUCTION
Depression is ranked as the single largest contributor to global disability 1 . It has been estimated that about 6% of the world's population suffer from depression 2 . In 2015, depression contributed 7.5% of all years lived with disability. 1 It is also a major contributor to suicide deaths, accounting for anywhere from half to two-thirds of suicide cases, which makes depression among the top 20 leading causes of death 1 . Depression results in high treatment costs for health care services and limits productivity in communities due to its associated long-term outcomes such as hypertension, diabetes emotional problems, and high disability, compared to other chronic diseases. 1 3 4 In 2010, it was estimated that the economic burden of depression in United States was US$210.5 billion 5 .
People with depression may experience various mental health effects, including persistently feeling low, a loss of interest and enjoyment, anxiety as comorbidity 6 and a range of emotional, cognitive, physical and behavioural symptoms 7 . Different symptoms together with daily problems may increase reluctant to engage in daily social activities and work. 8 Among other problems, almost two-thirds of individuals with depressive disorder have clinical anxiety as comorbidity of depressive disorder. 9 It has been reported in USA that a prevalence of anxiety in people with depression is 57.5% 10 . It has also found in the European cohort study that adults with depression and anxiety disorder had lower level of physical function compared to those without these conditions. In this study physical function referred to limitations in performing normal activities of daily living and mobility, such as personal hygiene and eating, or preparing meals and doing housework 8 . In institutional settings, among older people, apathy and depressive symptoms has found to be the greatest potential for limiting life space. 11 Life space refers to the area of movement extending from within the home to the geographic area a person moves in daily life 12 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The association between depressive symptoms and individual life space has been reported in previous studies 13 14 . Life-space mobility is a measurement of the space through which a person moves over a specific period of time 13 , and it is a way to view an individual's functioning and participation in real-world situations, as it measures the ability to walk, use public transportation or drive a car. 15 16 It is assumed that a larger life-space mobility provides more opportunities for an individual to engage with society, 17 while a restricted life-space mobility may reflect limited access to societal amenities. 18 19 It has been shown by Snih et al. that a high number of depressive symptoms is one of the contributing factors that is significantly associated with a lower level of life-space mobility. 14 Other studies have shown that a constricted life space may be related to negative health outcomes such as disability and cognition. 15 20-22 Boyle et al. 23 further indicate, in their prospective observational cohort study, that having a constricted life space is associated with a greater risk of mortality, while Cacioppo further proposes that having a larger life-space may contribute to the effective functioning of physiological systems, and therefore lead to better physical health outcomes. 24 Self-reported measurements have often been used to assess life-space mobility, yet although they can be helpful, they may tend to overestimate true mobility and underestimate sedentary time. 25 26 Therefore, more accurate and objective methods to detect human mobility are needed. 27 Understanding of association between objective behavioural features, for example physical activity, biometric, physical state and social behaviour, and depressive mood symptoms have provided new opportunities to use mobile applications and wearable devices for monitoring depression and other affective disorders 28 . It has been proposed that technological devices can 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 6 easily and objectively provide a way to monitor activity of people with these illnesses and could serve as a digital marker of mood symptoms 29 30 . We found two reviews related to the assessment of individual mobility using technological devices in patients with mental disorders. Burton et al., in their systematic review investigated the associations between objectively measured physical activity and depression using digital actigraphy in patients with depression 31 , where digital actigraphy is an objective measurement of activity using body-worn accelerometers 32 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 However, there is still a lack of knowledge about how mobility patterns and habits of people with depression in their course of illness can be measured using different technological devices to gain more understanding of these people's daily life. Rohani et al. 28 suggested that a standardized data collection method for physical activity and mobility features is needed, because there were limitations associated with different technologies used to measure mobility data in their review.
As a result, a wider knowledge should be available to identify how different technological devices
could be used to collect information of digital markers of life-space mobility in real-life community settings 31 . By doing this, in the future we would have better opportunities to tailor individuals' treatment plans based on their daily functioning and habits. Based on this knowledge, ideas for future development needs of technological devices could also be offered. However, in order to do this, we first need more knowledge about the tracking methods available and how these methods are used on a daily basis, keeping in mind their possible benefits and concerns.
AIM AND RSEARCH QUESTIONS
The overall aim of this systematic review is to describe the tracking technologies used in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This systematic review protocol is designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement Protocols (PRISMA-P) 33 This guideline is usable because PRISMA-P focuses on ways in which authors can ensure the transparent and complete reporting of systematic reviews and meta-analyses and facilitate the development and reporting of systematic review protocols. 34 The protocol has been registered in PROSPERO (number CRD42019127102).
METHODS AND ANALYSIS Design
A systematic review with narrative synthesis will be used to search, appraise and synthesise empirical evidence. This approach is useful for our purpose because narrative synthesis focuses on a wide range of questions, not only those relating to the effectiveness of a particular intervention. 35 
Eligibility criteria
PICO approach has been used to specify eligibility of the studies 36 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Diseases, ICD). Person with anxiety as co-morbidity will also be included since a high prevalence of anxiety comorbidity in depression 10 . We will exclude articles where subjects are diagnosed with bipolar disorder, schizophrenia, learning disabilities or other serious cognitive disorders. Articles involving only children or adolescents will also be excluded.
Intervention
All articles in which any type of tracking technology be included. Tracking technology can include mobile or wireless health, which refers to portable internal and wearable sensors to monitor health. 37 Other methods can include, for example, accelerometers, gyroscopes, vector magnetometers, goniometers, piezoelectric, and textile pressure sensors, electromyography, tilt/bend sensors and the global positioning system (GPS), which are able to measure the type, quantity, and quality of daily activity, movement and balance. 37 Methods used to track people movement or activity without technology, such as using written diaries, or questionnaires, will not be included.
Outcomes
The main outcome of the study will be type of tracking technologies used. The secondary outcomes are how the technology has been used, and what are outcome measurements used in tracking lifespace mobility among people with depression. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   10 Articles using any type of research design will be included as long as the study includes any type of the tracking technology used.
Study design
Other
Articles will be limited to peer-reviewed, published full-text articles. There will be no restriction regarding the language. In addition, theoretical papers, statistical reviews, books or book chapters, letters, dissertations, editorials and study protocols will be excluded.
Information sources
A comprehensive literature search with no specific year limits will be conducted. The following electronic databases will be searched: MEDLINE (via EbscoHost), CINAHL Complete, PsycINFO, Embase, the Cochrane Library (academic database for medicine and health science and nursing), Scopus, Web of Science (academic database across all scientific and technical disciplines, ranging from medicine and social sciences to arts and humanities), 38 Health technology assessment database (database for health technology) and IEEE Xplore (academic database for technology and engineering). These databases will be used because they allow us to search for literature widely in various disciplines related to our review topic. Moreover, a reference list of the selected papers will be screened to yield additional studies.
Search strategy
The search strategy will be elaborated upon and implemented prior to the study selection. We will use the PRISMA-P checklist for guidance. 33 Firstly, the existence of a controlled vocabulary thesaurus (such as MeSH terms, CINAHL headings, PsycINFO thesaurus) and their keywords will 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   11 be verified in each database. The search terms will be combined using the Boolean operators "AND" and "OR". Second, the following string of search terms will be used to ensure a broad coverage of published studies in this review: ("depression" OR "affective disorder*" OR "anxiety" OR "anxiety disorder*" OR "mental health" OR "mood disorder*" OR "unipolar" OR "mental disorder*") AND ("tracking" OR "tracking device*" OR "tracking technology*" OR "wearable device*" OR "wearable sensor*" OR "wearable technology*" OR "technology*") AND ("mobility" OR "life space"). Advice on searching will be sought from a faculty librarian regarding the keywords. An example of databases and search terms used, and references found is presented in Table 1 .
ANALYSIS
Data management
EndNote will be used to efficiently manage the retrieved records to help in documenting the process, streamlining document management and making the production of reference lists for reports and journal papers. EndNote will also be used to deal with duplications of selected papers and ensure that they are not treated as separate studies in the review. 39 
Selection process
There will be four steps in the study selection process (Figure 1 ). 30 First, titles and abstracts will be assessed by relevance to the inclusion criteria by two authors (CMH, MV) independently.
Second, the abstract of the papers will be screened for relevance and eligibility again by the same two authors (CMH, MV). Third, the full texts of the selected articles will be screened by the two authors (CMH, MV) for inclusion and exclusion criteria. In cases of any discrepancy on decisions made by the two authors, the paper will be discussed with another author (LSF). Papers that do not 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 12 meet the inclusion criteria will be rejected, and the reason (irrelevance or failure to meet the inclusion criteria) will be recorded to increase the transparency in the selection process. Fourth, the full texts of the studies that meet the inclusion criteria will be obtained for further detailed assessment. The reference lists of selected papers will also be screened and checked to find additional papers that meet the inclusion criteria.
Data collection process
Data items
Characteristics of the studies and population
Intervention
Details of tracking technologies used will be extracted: tracking technology used, characteristics of the tracking technology, administrator, length of tracking period, and possible challenges in using the tracking technology. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Outcomes
Extraction of the following information related to daily activity and community participation among the participants will be collected: specific outcomes, instruments used to measure the outcomes, the number of items and scoring for the instruments (total scale/subscales), and validity and reliability. Further, the following information of data items will be extracted to describe the daily activity and community participation patterns based on the outcomes measures used among the participants: the number of activities per day, time of day, type of activity, destination of the activity, and duration of activity.
Data extraction
Data of the selected papers will be extracted by one author (CMH) and inputted into predesigned tables to describe the characteristics of the included studies and to answer each review question; the process will be validated by MV. The division into tables will be reviewed by all authors.
Data synthesis
Initial descriptive synthesis will be conducted by tabulating details about study type, interventions, numbers of participants, and an overview of participant characteristics, to form a clear descriptive summary of the included studies 39 . The descriptive process will be conducted explicitly and rigorously, and decisions about how to group and tabulate data will be made based on the protocol and review questions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Appraisal of risk or methodological quality of the primary studies is an important step in systematic review, as it is used to decide if studies' results can be trusted. It will be resulted in bias during the review process if it fails to make objective decision on study designs and level of quality required 40 .
Risk of bias in individual studies
The quality of each study will be appraised using The Crowe Critical Appraisal Tool (CCAT).
The Crowe Critical Appraisal Tool has been designed based on a review of the design of 44 critical appraisal tools across all research designs 41 . The tool consists of eight categories (preliminaries, introduction, design, sampling, data collection, ethical matters, results and discussion) divided into 22 items, which are further divided into 98 item descriptors. 41 The combination of categories, items and item descriptors allows for a wide range of qualitative and quantitative health research to be appraised using one tool. [41] [42] [43] The scoring of the tool offers a combination of subjective and objective assessment. Each category is scored from 0 (the lowest score) to 5 (the highest score).
In addition, the Cochrane Collaboration's tool for assessing risk of bias in randomised trials will be used to assess the quality of selected randomised trial articles included in the review. 44 Each area to be assessed will be rated as "low risk", "high risk" or "unclear risk" of bias, and finally, overall quality of the article using RCT design will be rated as "good", "fair" or "poor".
Patient and public involvement
Patients will not be directly involved in the design of this study. As this is a protocol for a systematic review and no participant recruitment will take place, their involvement in the recruitment and the dissemination of findings to participants will not be applicable. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Amendments
Any amendments to this protocol will be documented with reference to saved searches and analysis methods, which will be recorded in bibliographic databases (Ovid), EndNote and Excel templates for data collection and synthesis.
Ethics and Dissemination
Because there will be no data collection involving human subjects in the actual systematic review, no ethical approval will be required. The results will be disseminated in a peer-review journal and a conference presentation.
Planned start and end date
The review is planned to start on 1 December 2019 and end on 30 November 2020.
DISSCUSSION
Second, this review will provide evidence of the use of tracking technologies in studying the lifespace mobility of adults with depression and/or anxiety disorder, which may provide new opportunities for further studies. Third, this review will be the first to combine the knowledge about existing tracking technology to be used to explore the life-space mobility among people with depression in real-time and real-world urban settings. However, we anticipate that there may be a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In conclusion, this systematic review will provide the best example of the use of tracking technologies in studying life-space mobility of adults with depression and/or anxiety disorder. The results from the review will inform and guide a future study on describing life-space mobility among people with depression in real-time and real-world urban settings in Hong Kong. Further, the results will provide insights for tailor-made rehabilitation services and policies, based on individual's concerns and needs.
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Funding
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
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Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 12 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
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